← All trials
NCT05970887
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2022
- Primary completion
- Dec 30, 2022
- Completion date
- Oct 12, 2023
- First posted
- Aug 1, 2023
- Last posted
- Oct 19, 2023
- Enrollment
- 154
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Catholic Kwandong UniversityLead sponsor
- Catholic Kwandong UniversityOverall official - principal investigator
- Catholic Kwandong UniversityReponsible party - principal investigator
- Korea UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.